Towards personalized treatment for early stage HER2-positive breast cancer

Nature Reviews Clinical Oncology, Published online: 13 December 2019; doi:10.1038/s41571-019-0299-9HER2-targeted therapy has greatly improved the outcomes of patients with HER2-positive breast cancer, with a range of agents now approved or in late-stage clinical development. In the era of precision medicine, efforts are being made to further improve patient outcomes by personalizing HER2-targeted treatment regimens, primarily though escalation or de-escalation of therapy according to the disease biology. In this Review, the authors provide an overview of the current landscape of HER2-targeted therapy and discuss the evidence supporting such tailored therapeutic strategies.

Source: Nature Reviews Clinical Oncology - December 12, 2019 Category: Cancer & Oncology Authors: Kristina Goutsouliak Jamunarani Veeraraghavan Vidyalakshmi Sethunath Carmine De Angelis C. Kent Osborne Mothaffar F. Rimawi Rachel Schiff Source Type: research